IL17A and bronchiectasis: Given significant differences between disease and control groups for age and use of ICS (either as monotherapy or as ICS/ LABA combination inhalers), multivariate regression analysis was undertaken (incorporating presence/ absence of bronchiectasis, ICS use, age, FEV1 as a percentage of the predicted value and gender) which showed no relationship between either of these variables and BALF IL-17A levels.